Featured speakers include William Mattes, Ph.D., Director, Toxicology, Critical Path Institute; Jackie Hunter, Ph.D., Senior Vice President, GlaxoSmithKline; Arthur Holden, Chairman and Chief Executive Officer, Serious Adverse Events Consortium; Ken Buetow, Ph.D., Associate Director for Bioinformatics and Information Technology and Director of Center for Biomedical Informatics and Information Technology, National Cancer Institute and Co-founder, caBIG™ and The BIG Health Consortium™; Rebecca D. Kush, Ph.D., President and Chief Executive Officer, CDISC; Robert Porter Lynch, Chief Executive Officer, The Warren Company, Chairman Emeritus, The Association of Strategic Alliance Professionals, Inc. (ASAP); and Jessica Nadler, Ph.D., AAAS Fellow for Policy and Technology Policy, Department of Health and Human Services.
Case studies of emerging consortia-based models and best practices will be featured from such consortia as The Innovative Medicines Initiative, The Critical Path Institute, The Serious Adverse Events Consortium, Biomarkers Consortia, EMEA, The Dundee Kinase Consortia, and Drug Safety and Toxicology Consortia.
Please visit www.healthtech.com/cbi/overview.aspx for more information.
About Cambridge Healthtech Institute (CHI)
Founded in 1992, Cambridge Healthtech Institute (CHI) (www.chicorporate.com) is the industry leader offering the preeminent source of information to the leading researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Hea
Copyright©2009 Vocus, Inc.
All rights reserved